Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Juergen B Bulitta"'
Autor:
Ashley N. Brown, Yinzhi Lang, Jieqiang Zhou, Evelyn J. Franco, Kaley C. Hanrahan, Juergen B. Bulitta, George L. Drusano
Publikováno v:
mBio, Vol 13, Iss 6 (2022)
ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral therapies to combat COVID-19, especially severe disease, remain s
Externí odkaz:
https://doaj.org/article/1665716aa8544c81845004b58cd2f18b
Autor:
Juergen B Bulitta, Beth Morgan, Günther Hochhaus, Christopher Wiggenhorn, David Christopher, Svetlana Lyapustina, Abhinav Kurumaddali, Helen Strickland, Dennis Sandell, Stephen W. Stein
Publikováno v:
AAPS PharmSciTech. 20
The performances of three statistical approaches for assessing in vitro equivalence was evaluated with a set of 55 scenarios of realistic test (T) and reference (R) cascade impactor (CI) profiles (originally employed by the Product Quality Research I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595bc7ff7177ed8453843942817ed324
https://doi.org/10.1208/s12249-019-1443-7
https://doi.org/10.1208/s12249-019-1443-7
Autor:
Nicholas M. Smith, Thomas P. Lodise, Katie Rose Boissonneault, Patricia N. Holden, Robert A. Bonomo, Juergen B Bulitta, Barry N. Kreiswirth, Brian T. Tsuji, Liang Chen
Publikováno v:
Open Forum Infectious Diseases
Background The scourge of MBLs among Gram negatives, such New Delhi Metallo-beta-lactamase-producing Klebsiella pneumoniae, has resulted in an overwhelming need for new treatmens. Worryingly, additional acquisition of plasmid-mediated polymyxin resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13a3498f9fd7cf98573031737ba695c
https://doi.org/10.1093/ofid/ofaa439.1507
https://doi.org/10.1093/ofid/ofaa439.1507
Autor:
Anna Maria Wolf, Juergen B. Bulitta, Claas Brockschmidt, Max Kurlbaum, Mathias Wittau, Evelyn Hemper, Jan Scheele, Doris Henne-Bruns
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:6241-6247
Meropenem serves as a clinically important, broad-spectrum antibiotic. While meropenem is commonly used in obese patients, its pharmacokinetics in this patient group is not well known. Our aim was to characterize the population pharmacokinetics and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16c136acea8e29dd6a62c81348315a2
https://doi.org/10.1128/aac.00259-15
https://doi.org/10.1128/aac.00259-15
Autor:
Jason A. Roberts, Therese Starr, Melissa Lassig-Smith, Juergen B. Bulitta, Janine Stuart, Yoshiro Hayashi, Jeffrey Lipman, Rachel Dunlop, Andrew A. Udy, Steven C. Wallis, Natasha Anne Roberts, Paul Jarrett
Publikováno v:
The Journal of antimicrobial chemotherapy. 69(9)
Free to read on publisher's website Objectives Doripenem is a newer carbapenem with little data available to guide effective dosing during renal replacement therapy in critically ill patients. The objective of this study was to determine the populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645fb3aedd610ba2d070b60d11396123
https://pubmed.ncbi.nlm.nih.gov/24879665
https://pubmed.ncbi.nlm.nih.gov/24879665
Autor:
Hartmut Lode, Olaf Burkhardt, Mareike Rau, Michael Kurowski, Juergen B. Bulitta, Mathias W. Pletz, Guido Kruse, Carl Erik Nord, Andrés de Roux
The pharmacokinetics of ertapenem and ceftriaxone were investigated in an open, randomized, two-period crossover study after single- and multiple-dose administration in 10 healthy volunteers (five women and five men). Both antibiotics were administer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e7287b3ad3b92e08764906f1a9798c1
https://europepmc.org/articles/PMC521887/
https://europepmc.org/articles/PMC521887/
